Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics (NQ: SRPT )

114.23 +3.73 (+3.38%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Why This Sarepta Therapeutics Is Turning Bullish
Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) jumped in early trading on Wednesday, after the company reported an earnings beat for its fourth quarter. 
Via Benzinga
3D Systems, CarGurus, Sarepta Therapeutics And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded lower, with the Dow Jones dropping around 80 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Sarepta Rockets And Breaks Out As FDA Smooths The Path For Its Gene Therapy
The FDA will not hold an advisory committee meeting for the company's gene therapy. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2023
Via Benzinga
Novavax Stock Down On Concern Over Whether The Company Can Continue
Novavax warns that it may not be able to continue as a company. 
Via Talk Markets
Why Is Sarepta Therapeutics (SRPT) Stock Up 21% Today?
Sarepta Therapeutics (SRPT) stock is heading higher on Wednesday following the release of its latest earnings report and an upgrade. 
Via InvestorPlace
Investors Just Hit the Jackpot on These 2 Nasdaq Biotech Stocks
Markets are trying to rise, and these companies are helping out. 
Via The Motley Fool
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Sarepta Therapeutics To Rally Over 53%? Here Are 10 Other Analyst Forecasts For Wednesday
Keybanc raised the price target for Ambarella, Inc. (NASDAQ: AMBA) from $95 to $105. Keybanc analyst John Vinh maintained an Overweight rating. Ambarella shares fell 7.1% to $87.61 in pre-market... 
Via Benzinga
Why Reata Pharmaceuticals Shares Are Trading Higher By 140%; Here Are 20 Stocks Moving Premarket
Gainers Reata Pharmaceuticals Inc (NASDAQ: RETA) rose 140.8% to $75.06 in pre-market trading after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia. 
Via Benzinga
Expert Ratings for Sarepta Therapeutics
Via Benzinga
9 Analysts Have This to Say About Sarepta Therapeutics
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time to start the day with another breakdown of the biggest pre-market stock movers traders need to know about on Wednesday! 
Via InvestorPlace
Sarepta Therapeutics (SRPT) Q4 2022 Earnings Call Transcript
SRPT earnings call for the period ending December 31, 2022. 
Via The Motley Fool
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
BTIG Maintains Buy Rating for Sarepta Therapeutics: Here's What You Need To Know
Via Benzinga
Analyst Ratings for Sarepta Therapeutics
Within the last quarter, Sarepta Therapeutics (NASDAQ:SRPT) has observed the following analyst ratings: 
Via Benzinga
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate Developments
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics Announces Call for Applications for the 6th Annual Route 79, The Duchenne Scholarship Program
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2022 Financial Results
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics Announces Initiation of VOYAGENE, a Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
From Sarepta Therapeutics, Inc.
Via Business Wire
Earnings Scheduled For February 28, 2023
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its fourth quarter. 
Via Benzinga
3 Gene Editing Stocks With the Best Long-Term Potential
These gene editing stocks are likely to deliver massive gains ahead in the fast-evolving biotech space 
Via InvestorPlace
7 Biotech Stocks That Will Make You Rich in 10 Years
Although the health innovation space is risky, the opportunities beckon a look at the biotech stocks that will make you rich in 10 years. 
Via InvestorPlace
2 Under-the-Radar Biotech Stocks to Buy in 2023
These biotechnology stocks are pushing ahead with promising innovations. 
Via The Motley Fool
Sarepta and Catalent Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate
From Catalent, Inc.
Via Business Wire
2 Top Healthcare Stocks to Buy for the Long Haul
These two companies are just getting started. 
Via The Motley Fool
Stock Market Rally Fights At Key Level On Powell, Inflation Data, Jobs Report: Weekly Review
The S&P 500 is fighting for its 200-day, a critical level for the uptrend. 
Via Investor's Business Daily
Sarepta Surges As It Nears The Finish Line With A Muscular Dystrophy Gene Therapy
Sarepta Therapeutic is nearing the finish line with its Duchenne muscular dystrophy gene therapy. 
Via Investor's Business Daily
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback